Dr. Gopalakrishnan has been working in the field of CNS diseases since 2004. She is currently vice president, pre-clinical and pharmaceutical development, at Neuraltus Pharmaceuticals Inc., a privately held biopharmaceutical company dedicated to developing and commercializing high impact, small molecule products that address critical unmet needs in the treatment of neurodegenerative diseases. She will be overseeing all collaborative programs with Dr Amy B. Manning-Bo?, the Co-PI, and SRI International. Dr. Gopalakrishnan has over 15 years of research and development experience in academia and the pharmaceutical/biotech industry. The breadth of her experience spans early (pre-clinical/Phase 1) to late stage (Phase 2/3) drug development in various therapeutic areas including CNS disorders. She successfully led a CNS clinical development program through Phase 2/3 development leading to a NDA submission.

Dr. Gopalakrishnan holds a PhD from National Chemical Laboratory/Poona University, India in the area of RNA synthesis and characterization. She subsequently held post-doctoral positions at Penn State University and Stanford University School of Medicine and has over 20 peer reviewed publications.